Details for 2013177190

Up to date per 04.04.2026

Actions

Title / Product Name

HEMIFUMARATSALZ VON 1-[4-[1-(4-CYCLOHEXYL-3-TRIFLUORMETHYLBENZYLOXYIMINO)-ETHYL]-2-ETHYLBENZYL]AZETIDIN-3-CARBONSÄURE ZUR BEHANDLUNG VON LYMPHOCYTENVERMITTELTEN KRANKHEITEN

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2013177190

EP Publication Number

2676953

E-Number

877586

Language

PCT Number

Publication Date

25.12.2013 A

22.03.2017 B1

Registration Date

22.03.2017

AT Publication Date

15.04.2017

Application Date

16.12.2009

Registration Number

Priorities

18.12.2008

203053 P

IPC

C07D 205/04 20060101AFI20131115BHEP

Maximum Duration of Protection

16.12.2029

Owner

Novartis AGLichtstrasse 35 4056 BaselCH

Representative

SCHWARZ & PARTNER PATENTANWÄLTE OGWipplingerstraße 301010 WienAT

Inventor

Ciszewski, LechNovartis One Health Plaza East Hannover, NJ New Jersey 07936US

De La Cruz, MarilynNovartis One Health Plaza East Hannover, NJ New Jersey 07936US

Karpinski, Piotr H.Novartis One Health Plaza East Hannover, NJ New Jersey 07936US

Mutz, MichaelNovartis Pharma AG Postfach 4002 BaselCH

Riegert, ChristianNovartis Pharma AG Postfach 4002 BaselCH

Vogel, CasparNovartis Pharma AG Postfach 4002 BaselCH

Sschneeberger, RicardoNovartis Pharma AG Postfach 4002 BaselCH

Information about Fees